# A Nomogram Incorporating Sarcopenia and Nutritional Indicators for Mortality Prediction in HBV-Related Acute-Chronic Liver Failure

**Authors:** Jiao Yuan, Wenting Peng, Chuan Jiang, Hui Liu, Shuo Wang, Ying Jiang, Bin Tan, Lei Fu, Shifang Peng

PMC · DOI: 10.3390/healthcare14040447 · 2026-02-11

## TL;DR

This study creates a tool to predict 12-week mortality in patients with HBV-related liver failure by combining nutritional and muscle indicators with traditional factors.

## Contribution

A novel nomogram integrating sarcopenia and nutritional indicators for mortality prediction in HBV-related ACLF patients.

## Key findings

- The nomogram achieved high discrimination with an AUC of 0.95 for predicting 12-week mortality.
- Incorporating nutritional indicators like ceruloplasmin and skeletal muscle index improved risk stratification.
- The model showed excellent calibration and clinical utility through validation methods.

## Abstract

Background: The prognosis of acute-on-chronic liver failure (ACLF) is impaired by etiology heterogeneity across regions. Currently, prognostic models incorporating nutrient anabolism–related indicators for patients with hepatitis B virus (HBV)–associated ACLF are lacking. Objectives: This study aimed to construct a nomogram that incorporates nutrition-related indexes alongside traditional predictors to estimate 12-week mortality in HBV-ACLF. Methods: We retrospectively analyzed adult patients with HBV-ACLF treated at our department between May 2020 and December 2021. A total of 242 HBV-ACLF patients were enrolled and categorized into survivor (n = 174) and progression (n = 68) groups. Independent prognostic factors were identified using logistic regression analysis and incorporated into a nomogram. Nomogram performance was evaluated in terms of discrimination, calibration, and clinical utility, with internal validation using bootstrap resampling. Results: Patients in the progression group were older, more prone to hepatorenal syndrome and spontaneous peritonitis, and had lower levels of prothrombin activity, L3 skeletal muscle index and ceruloplasmin (all p < 0.05). These six independent predictors were incorporated into the nomogram, which demonstrated superior discrimination ability, with an area under the receiver operating characteristic curve of 0.95, enabling accurate identification of patients at high risk of short-term mortality. The Hosmer–Lemeshow test confirmed excellent calibration, decision curve analysis confirmed the clinical benefit, and bootstrap validation confirmed the robustness. Conclusions: The developed nomogram, incorporating nutritional status, may provide complementary information to support short-term risk stratification and clinical decision-making in patients with HBV-ACLF awaiting liver transplantation.

## Linked entities

- **Diseases:** hepatorenal syndrome (MONDO:0001382)

## Full-text entities

- **Genes:** GPT (glutamic--pyruvic transaminase) [NCBI Gene 2875] {aka AAT1, ALT, ALT1, GPT1, SGPT}, CP (ceruloplasmin) [NCBI Gene 1356] {aka AB073614, CP-2}, C3 (complement C3) [NCBI Gene 718] {aka AHUS5, ARMD9, ASP, C3a, C3b, CPAMD1}, PTCRA (pre T cell antigen receptor alpha) [NCBI Gene 171558] {aka IMD126, PT-ALPHA, PTA}, F2 (coagulation factor II, thrombin) [NCBI Gene 2147] {aka PT, RPRGL2, THPH1}
- **Diseases:** Acute Kidney Injury (MESH:D058186), non-alcoholic steatohepatitis (MESH:D005235), hematemesis (MESH:D006396), Nutritional anabolic disorders (MESH:D009748), immunodeficiency disorders (MESH:D000081207), alcoholism (MESH:D000437), CER (MESH:C536004), Cirrhosis (MESH:D005355), injury to (MESH:D014947), chronic liver disease (MESH:D008107), Sarcopenia (MESH:D055948), HBV (MESH:D006509), alcoholic, autoimmune, or hepatitis C- (MESH:D019698), HRS (MESH:D006530), liver cirrhosis (MESH:D008103), intra-abdominal infection (MESH:D059413), malignancies (MESH:D009369), brain and kidney failure (MESH:D051437), SP (MESH:D010534), liver and clotting failure (MESH:D017093), HE (MESH:D006501), hepatic protein synthesis (MESH:D056486), chronic hepatitis B (MESH:D019694), alcohol-related liver disease (MESH:D008108), chronic extrahepatic disease (MESH:D002908), GIB (MESH:D006471), hepatocyte necrosis (MESH:D009336), hepatocellular carcinoma (MESH:D006528), fungal or viral infections (MESH:D014777), melena (MESH:D008551), acute injury (MESH:D001930), Malnutrition (MESH:D044342), End-Stage Liver Disease (MESH:D058625), Acute-Chronic Liver Failure (MESH:D065290), Ascites (MESH:D001201), portal hypertension (MESH:D006975), deterioration of liver function (MESH:D017114), peritonitis (MESH:D010538), infection (MESH:D007239)
- **Chemicals:** copper (MESH:D003300), TAF (MESH:C442442), TDF (MESH:D000068698), bilirubin (MESH:D001663), creatinine (MESH:D003404), alcohol (MESH:D000438), triiodothyronine (MESH:D014284), Na (MESH:D012964), bile acid (MESH:D001647), FT3 (-), thyroxine (MESH:D013974), ETV (MESH:C413685), urea (MESH:D014508), amino acid (MESH:D000596)
- **Species:** Hepatitis B virus (no rank) [taxon 10407], Homo sapiens (human, species) [taxon 9606]

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12940219/full.md

---
Source: https://tomesphere.com/paper/PMC12940219